Evaluation of the Performance and Safety of a Medical Device Developed to Improve the Reading of Dyslexic Patients
NCT ID: NCT04157829
Last Updated: 2021-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
33 participants
INTERVENTIONAL
2019-12-18
2021-01-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurofeedback Training for Dyslexia
NCT04989088
Visual Attention Span Mobilisation for Dyslexia
NCT05201235
Assessment of Visual Dyslexia Remediation Protocols - Dyslexia REMEDIATION
NCT05514457
Dyslexics' Visual Attention Field
NCT03285789
Reading; Through the Eyes of a University Student
NCT04318106
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Dyslexia appears in the child from the earliest stages of learning in the form of a difficulty in mastering the learning of reading. This disorder is manifested by a generally hesitant reading, slowed down, full of errors, requiring a lot of effort for the child and may impact his reading comprehension. The dyslexia-related deficiency is of variable intensity depending on the individual; it may be accompanied by calculus disorders (dyscalculia), oral language (dysphasia), motor coordination (dyspraxia) or attention disorders with or without hyperactivity. In nearly 40% of cases, a child affected by Dys disorders presents several learning disorders.
To date, the causes of dyslexia are not yet clearly established. The wide variety of symptoms and disorders associated with dyslexia does not facilitate the identification of precise neurobiological / psycho cognitive mechanisms. There are therefore several theories: phonological, visual, temporal, cerebellar or proprioceptive auditory processing.
Recently, following work published in 2017, an anatomical cause based on Maxwell's spots could also be a cause of dyslexia.
The aim of this study is to evaluate a new medical device to compensate this probable anatomical cause.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Scintilling lamp- Classic lamp
Scintilling lamp
Lamp with a standardized scintilling
Classic lamp
Lamp without a scintilling
Classic lamp- Scintilling lamp
Scintilling lamp
Lamp with a standardized scintilling
Classic lamp
Lamp without a scintilling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Scintilling lamp
Lamp with a standardized scintilling
Classic lamp
Lamp without a scintilling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* French mother tongue,
* For whom developmental dyslexia has been diagnosed by a health professional who specializes in this learning disorder,
* Presenting an IQ ≥ 80 and ≤130 according to the WISC-V test performed by a psychologist,
* For which a written consent was obtained regarding his study participation.
Exclusion Criteria
* Presenting a developmental disorder (autism, ADHD, ...),
* Presenting hearing disorders,
* Presenting visual disorders,
* Any other condition that, in the opinion of health professionals, could impair its ability to complete the study or could pose a significant risk.
8 Years
11 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Slb Pharma
OTHER
SATT Ouest Valorisation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine Allaire, Dr
Role: PRINCIPAL_INVESTIGATOR
CHU Rennes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr Laurence Derieux
Caen, , France
Dr Luc-Marie Virlet
Faumont, , France
Dr Hugo Peyre
Paris, , France
Dr Catherine ALLAIRE
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DysLight
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.